An Open-label, Multicentre, Single-arm Safety and Efficacy Clinical Investigation of Diagnostic Microprobe (inPROBE) for the Assessment of HER2 Receptor Expression in Population of Women at High Risk of Breast Cancer

SDS Optic S.A.2 sites in 1 country18 target enrollmentAugust 24, 2022

ConditionsBreast Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Breast Cancer
Sponsor: SDS Optic S.A.
Enrollment: 18
Locations: 2
Primary Endpoint: Preliminary determination of HER2 receptor concentration ranges detected with inPROBE corresponding to HER2 receptor status (positive/negative) as determined by current diagnostic standard (IHC/FISH).
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to preliminarily determine the correlation of HER2 receptor levels detected with the inPROBE diagnostic probe relative to receptor status as determined by standard methods (IHC/FISH), in women with both HER2-positive and HER2-negative breast cancer.

Registry

clinicaltrials.gov

Start Date

August 24, 2022

End Date

March 2, 2023

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Female

Investigators

Sponsor

SDS Optic S.A.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Provision of written informed consent to participate in the clinical investigation;
•Female patient aged ≥ 18 to ≤ 75 years;
•The patient's overall health status as determined by Eastern Cooperative Oncology Group (ECOG) from 0 to 1;
•Preserved full ability to communicate with the investigator and to understand and comply with the requirements of the Clinical investigation plan;
•High likelihood of attending follow-up appointments in accordance with the study design and completing this study in accordance with this Clinical investigation plan.
•The presence of a malignant neoplasm (breast cancer) confirmed by histopathologic examination of material from a gross needle biopsy of the tumor, with specific HER2 receptor status.
•Patient referred for surgical treatment of breast cancer.

Exclusion Criteria

•History of treatment with trastuzumab, or other HER 2 receptor-binding antibody, as part of neoadjuvant (induction) therapy for currently diagnosed and treated breast cancer.
•A skin disorder that prevents or contraindicates to perform a probe examination in the opinion of the investigator;
•Breast inflammation/infection on the day of the probe examination;
•Allergy to any component of the medical device that is the subject of this clinical investigation;
•An implant in the breast where the inPROBE study and surgery will be performed;
•Any physical or psychiatric condition, or laboratory test values outside the normal range, which in the opinion of the investigator constitute a contraindication to the patient's participation in this clinical investigation or pose a risk of exclusion from the study or premature termination of participation in the study;
•Any clinically significant abnormality in physical examination, vital signs, or laboratory tests that, in the opinion of the investigator, is a contraindication to participation in this clinical trial;
•Pregnancy or breastfeeding;
•Participation in another clinical trial within 30 days prior to signing informed consent to participate in this clinical investigation;

Outcomes

Primary Outcomes

Preliminary determination of HER2 receptor concentration ranges detected with inPROBE corresponding to HER2 receptor status (positive/negative) as determined by current diagnostic standard (IHC/FISH).

Time Frame: Day 1

Secondary Outcomes

The occurrence of defects, failures, and fractures of the inPROBE probe during the diagnostic procedure leading to AE/ SAE.(Day 1 - Day 14)
Comparison of the correlation of HER2 receptor concentrations detected by the inPROBE probe located in the tumor and in the immediate tumor area in HER2 positive patients.(Day 1)